SA012 is a First-in-Class (FIC) siRNA product targeting hepatocyte PD-L1 mRNA. Compared to traditio nal anti-PD-L1 monoclonal antibody treatments for chronic hepatitis B,β it has unique advantages: 1) More precise targeting：© SA012 acts on hepatocyte PD-L1, restoring the function ​of exhausted HBV-specific CD8+ T cells, playing an antiviral role; 2) Superior efficacy：Due to× its good safety profile, SA012 allows for increased the dosage in clinical use, ensuring suf÷ficient and sustained efficacy; 3) Better safety: The precise hepatic targeting of SA012 can avoid¶ or reduce systemic immune side effects, improving patient compliance.

SA012 is a First-in-Class (FIC) siRNA product targeting hep§atocyte PD-L1 mRNA. Compared to traditional anti-PD-L1 monoclonal an←tibody treatments for chronic hepatitis B, it has un↕ique advantages: 1) More precise targeting： SA012 acts♥ on hepatocyte PD-L1, restoring the function of exhausted HBV-specific CD8+ T ce​lls, playing an antiviral role; 2) Superior efficacy：Due to its g ood safety profile, SA012 allows for increased the dosage in clinic$al use, ensuring sufficient and sustained efficacy; 3) Better safety: The prec©ise hepatic targeting of SA012 can avoid or reduce systemic immune side effects, imp♥roving patient compliance.

The research results show that SA012 can achieve the best-in-class∏ clearance of HBsAg, with good safety. A single administration of SA012 effectively anλd sustainably cleared HBsAg and HBV DNA in humanized PD-1/PD-↑L1 AAV-HBV mice, with 5/7 and 4/7 of the mice reaching the low‌er limits of detection for HBsAg and HBV DNA, respectively. At the end of t​he experiment, 5/7 of the mice achieved seroconversi<on of HBsAg. When SA012 was used in combination with other an♦ti-HBV drugs (such as VIR-2218 or Bepirovirsen), &>nbsp;significant synergistic effects were observed, and no viral reb✔ound was observed throughout the study.

SA012 helps restore HBV-specific acquired immunity, which may b↔e key to preventing viral rebound. Due to its unique mechanism of action, SA012 has great pote ntial in the functional cure of chronic hepatitis B as a monotherapy and in combination wi×th other types of antiviral drugs.

This conference not only highlighted the foresight and professionalism of Siran Bio in the fieλld of chronic hepatitis B drugs, but also further strengthened exchanges and cooperation with ind€ustry peers. Siran Bio will continue to be committed to promoting t•he research,development and application of siRNA technology, and bringing ¥more new treatment options to global chronic hepatitis B patients.

About the European Association for the Study of the Liver (EASL)

Established in 1966, EASL is the largest liver disease research org§anization in Europe, with over 4,500 members worldwide. Since its inception, EASL has grown from aπ small organization to an influential international organization. Its∏ mission is to promote research in hepatology; provide state-of-the-art education for∞ physicians and scientists; and raise public awareness of liv'er diseases and their management, enabling all those involved€ in liver disease research to reach their full potential and be come experts in the field, curing and preventing liver diseas>es. The annual EASL conference attracts more than 7,000 professionals from over 100 c♣ountries worldwide. Participants of the EASL conference include scienti£fic and medical experts in the fields of hepatology, gastroenterology, internal medicine, cell b¥iology, transplant surgery, infectious diseases, microbiology, virology, δpharmacology, pathology, radiology, and numerous media representatives.

About Siran Bio

Siran Bio was established in Suzhou Industrial Park in May 2022. It is a biotechnology company ✘focused on the development of innovative siRNA drugs, founded by a top scient★ific team in the field of nucleic acid therapy and an ind↑ustrialization expert team.It has received support from the Suzhou Industrial P<ark's leading and Gusu leading enterprises.

The company has established an industry-leading dual-target nucleic acid drug techno÷logy platform and extrahepatic delivery platform with proprieta$ry intellectual property rights, including eSAFE chemical modification tec​hnology and STORK intrahepatic and extrahepatic delivery tech↕nology platforms. Based on its leading technology platform, the company has rapidl×y developed a pipeline of small nucleic acid drugs for antiviral, cardiovascular and™ metabolic diseases, autoimmune, and central nervous sys§tem-related diseases.

The company always takes patients as the center, committed to the in₩telligent manufacturing of the best small nucleic ∞acid drugs, addressing unmet clinical needs, and enhancing human health and happiness.